Abeona Therapeutics Inc. ABEO
Abeona Therapeutics Inc. (Nasdaq: ABEO) is a rare genetic drug developer. Its lead program, ZEVASKYN (prademagene zamikeracel), is in Pre-clinical for Wounds in recessive dystrophic epidermolysis bullosa (RDEB).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| ZEVASKYN (prademagene zamikeracel) | RDEB wounds | gene therapy | Approved |
| ABO-701 (PSMA-SIR-T) | PSMA-expressing solid tumors | cell therapy | Pre-clinical |
| AIM capsid AAV ophthalmic gene therapies | ophthalmic diseases | gene therapy | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.